1) Airaksinen O, Brox JI, Cedraschi C, et al:Chapter 4. European guidelines for the management of chronic non-specific low back pain. Eur Spine J 15:S192-S300, 2006
2) Bamigbade TA, Davidson C, Langford RM, et al:Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth 79:352-356, 1997
3) Dhillon S:Tramadol/paracetamol fixed-dose combination:a review of its use in the management of moderate to severe pain. Clin Drug Investig 30:711-738, 2010
4) Driessen B, Reimann W:Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol 105:147-151, 1992
5) Hennies HH, Friderichs E, Schneider J:Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 38:877-880, 1988
6) Ikemoto T, Ushida T, Tanaka S, et al:Painful mechanical stimulation evokes activation of distinct functional areas in the brain:comparison of normal subjects and two patients with neuropathic pain. Pain Research 18:137-144, 2003
7) McCarberg B:Tramadol extended-release in the management of chronic pain. Ther Clin Risk Manag 3:401-410, 2007
8) 満島 隆,川面 博,石井敏行・他:新鎮痛薬1-(m-methoxyphenyl)-2-dimethylamino methyl cyclohexanol (1) hydrochloride(K-315)の薬理学的研究.第3報:K-315の鎮痛効果と脳内CA,5-HTとの関係について.日薬理誌68:437-445,1973
9) Recommendations for the medial management of osteoarthritis of the hip and knee. 2000 update American Collage of Rheumatology. Subcommittee on osteoarthritis guide lines. Arthritis Rheum 43:1905-1915, 2000